Trial results

Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

NCT06339086 on ClinicalTrials.gov · last registry update 2024-04-01

478 participants. Its estimated completion date, 30 August 2025, has passed with no update to the record. Primary outcome, as filed: Change in HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

UNKNOWN

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Chengdu Brilliant Pharmaceutical Co., Ltd.

Sponsor type

Industry

Enrollment

478

Started

2024-04

Primary completion

2025-08-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.